EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution–Based Antiretroviral Therapy

Lisa L Ross, Mark F Cotton, Haseena Cassim, Harmony P Garges, Sven C van Dijkman, Kishen Morarji, Supriya Karthika, Susan Danehower, Jacob Radford, David Butcher

AIDS Research and Human Retroviruses · 2024

DOI: 10.1089/aid.2024.0020 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift AIDS Research and Human Retroviruses, 2024. Verfasst von Lisa L Ross und 9 weiteren Autor:innen. Beteiligte Einrichtung: ViiV Healthcare, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: HIV Infections, Ritonavir, Carbamates, Sulfonamides. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

APV20002 was a multicenter, international, open-label study that began in 2003 investigating the pharmacokinetics, efficacy, and safety of ritonavir-boosted fosamprenavir (FPV/r) oral solution (OS) in combination with nucleoside reverse transcriptase inhibitor-based antiretroviral therapy (ART) in participants living with HIV-1 aged 4 weeks to 39 kg or if FPV OS had no clinical benefit. Fifty-nine participants were enrolled; 5/59 received a single FPV OS visit for pharmacokinetic determinations. Most (38/54; 70%) were antiretroviral experienced; 39/59 participants had >48 weeks on treatment, 4/39 of whom discontinued after 48 weeks due to an adverse event (AE). At 48W, 88% of participants had HIV-1 RNA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsRitonavirCarbamatesSulfonamidesHIV-1FuransOrganophosphatesViral LoadHumansMaleFemaleInfantTreatment OutcomeAnti-HIV AgentsAdministration, OralChild, PreschoolAntiretroviral Therapy, Highly ActiveInfant, NewbornCD4 Lymphocyte Count

Stichwörter der Autor:innen

HIV-1antiretroviral therapypediatricritonavir–boosted fosamprenavir oral solution

Substanzen

RitonavirfosamprenavirCarbamatesSulfonamidesFuransOrganophosphatesAnti-HIV Agents

Autor:innen und Institutionen

  • ViiV Healthcare, Durham, North Carolina, USA.
  • Department of Pediatrics and Child Health, Children's Infectious Diseases Clinical Research Unit, Stellenbosch University, Tygerberg, South Africa.
  • Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
  • GlaxoSmithKline, Brentford, United Kingdom.
  • ViiV Healthcare, Brentford, United Kingdom.

Zitieren

APA

Ross, L. L., Cotton, M. F., Cassim, H., Garges, H. P., van Dijkman, S. C., Morarji, K., Karthika, S., Danehower, S., Radford, J., & Butcher, D. (2024). Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution–Based Antiretroviral Therapy. AIDS Research and Human Retroviruses. https://doi.org/10.1089/aid.2024.0020

Vancouver

Ross LL, Cotton MF, Cassim H, Garges HP, van Dijkman SC, Morarji K, et al. Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution–Based Antiretroviral Therapy. AIDS Research and Human Retroviruses. 2024. doi:10.1089/aid.2024.0020

BibTeX
@article{Ross2024,
  author = {Ross, Lisa L and Cotton, Mark F and Cassim, Haseena and Garges, Harmony P and van Dijkman, Sven C and Morarji, Kishen and Karthika, Supriya and Danehower, Susan and Radford, Jacob and Butcher, David},
  title = {Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution–Based Antiretroviral Therapy},
  journal = {AIDS Research and Human Retroviruses},
  year = {2024},
  doi = {10.1089/aid.2024.0020}
}
Kostenlos starten →